BCL 2 (Ab 56) Antilichaam

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) .

596

P10415

NP_000624.2

Human

BCL-2 (Ab-56) antibody was raised against a peptide sequence around aa. 54~58 (G-H-T-P-H) derived from Human BCL-2.

Unconjugated

Primary Antibodies

Apoptosis, Cancer

Antibodies were purified by affinity-chromatography using epitope-specific peptide.

1 mg/mL

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

None

Blue Ice

Store antibody at -20˚ C for up to one year.

26 kDa

This antibody detects endogenous level of total BCL-2 protein.

Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100, Immunofluorescence: 1:100~1:200

BCL2

B-cell CLL/lymphoma 2

Homo sapiens

Ling, Y. H. et al. (1998) J. Biol. Chem. 273, 18984-18991. Huang, S. J. and Cidlowski, J. A. (2002) FASEB 16, 825-832. Deng, X. et al. (2001) J. Biol. Chem. 276, 23681-23688. Huang ST, et al. (2002) FASEB J Jun; 16 (8) : 825-32. Yamamoto, K. et al. (1999) Mol. Cell. Biol. 19, 8469-8478.

Bcl-2, PPP1R50, OIP3, PK2, PK3, PKM2, BCL2

WB, IHC, IF

72198189

Liquid